Batten Disease News

Skip to content
  • Home
  • What is Batten Disease?
    • Living with Batten Disease
      • Seizure Alarms
      • Seizure Diaries
      • Seizure First Aid
      • Batten Disease and Education
      • Speech Therapy
      • Anxiety and Depression
      • Adaptations and Equipment
      • Genetic Counseling
      • Tube Feeding
      • Emergency Seizure Management Plan
    • Physiotherapy and Occupational Therapy
    • Batten Disease Symptoms
      • Types of Seizures
        • Seizure Warning Signs
        • Focal Impaired-Awareness Seizures
        • Jacksonian Seizures
        • Seizure Triggers and Batten Disease
        • Partial Seizures
        • Status Epilepticus
        • Generalized Seizures
        • Simple Partial Seizures
      • Batten Disease and Vision
      • Batten Disease and Sleep
    • Batten Disease Types
      • Infantile Batten Disease
      • Adult Batten Disease
      • Juvenile Batten Disease
      • Late Infantile Batten Disease
      • Congenital Batten Disease
    • Batten Disease Prognosis
    • Batten Disease Diagnosis
      • Enzyme Assays
      • Tissue Biopsy
      • Urine Tests
      • Blood Tests
      • Eye Tests
      • Batten Disease Screening
      • Tests of Brain Changes
    • Batten Disease Causes
  • Batten Disease Treatment
    • Vagus Nerve Stimulation
    • Rescue Medications
      • Midazolam
      • Nayzilam (USL261)
      • Ativan (Lorazepam)
    • Gene Therapy
    • Benzodiazepines
      • Tranxene T-Tab (Clorazepate)
    • Lysosomal Treatments
    • Anticonvulsants
      • Cerebyx (Fosphenytoin)
      • Keppra (Levetiracetam)
      • Lamictal (Lamotrigine)
      • Valproic Acid
      • Diazepam
      • Klonopin (Clonazepam)
      • Onfi (Clobazam)
    • Immunosuppressants
    • Brineura Approved!
    • RNA Treatments
    • Small Molecule Therapy
    • Enzyme Replacement Therapy
    • Experimental Treatments
      • PLX-200
      • PLX-100
      • Stem Cell Treatment
      • ABO-201
      • ABO-202
      • CellCept
  • Columns
    • The Long Sprint

Clinical Evolution of Batten Disease in Young Adult Siblings Described in Case Report

May 25, 2018May 25, 2018
Patricia Inacio, PhDby Patricia Inacio, PhD

In News.

Clinical Evolution of Batten Disease in Young Adult Siblings Described in Case Report

Click here to subscribe to the Batten Disease News Newsletter!

Long-term follow-up of two siblings with Batten disease unveiled symptoms of slowly progressive motor deterioration, persistent photosensitivity, and seizures without dementia, according to a case report.

The case report, “Long-term follow-up of two siblings with adult-onset neuronal ceroid lipofuscinosis, Kufs type A,” was published in the journal Epileptic Disorders.

Researchers analyzed the medical records of two Turkish siblings, whose parents are first cousins, diagnosed with adult-onset neuronal ceroid lipofuscinoses (NCLs), also known as Batten disease, linked to a mutation in the CLN6 gene.

NCLs are a group of inherited, neurodegenerative disorders characterized by progressive intellectual and motor deterioration, seizures, and early death. Vision loss is a feature of most forms of Batten disease.

While the features of infantile- and childhood-onset forms have been widely reported, that of juvenile- or adult-onset NCLs are still scarce.

Both siblings — an 18-year-old-girl and a 26-year-old man — had seizures and cerebellar signs, with slow progression of ataxia, or impairments in coordination, balance, and speech. They showed no signs of mental deterioration, but had severe obsessive-compulsive disorder and depression.

Their electroencephalogram (EEG) exams — a test that records the electrical activity of the brain by picking up electrical signals from brain cells — showed generalized spikes of electrical activity and slow waves during the periods they were awake and during visual stimulation, without significant changes throughout the clinical course.

Both patients had normal brain scans, assessed using magnetic resonance (MRI) imaging, at disease onset. Both developed gradual and progressive degeneration of the outer layer of the brain, known as cortical atrophy. This degeneration was more prominent in the girl, who had more severe clinical findings and longer disease duration.

She began treatment with carbamazepine (an anti-epileptic treatment sold under the brand name Tegretol, among others) but switched to valproate (an anti-convulsant sold in the U.S. as Depakene) at 500 mg/day after lack of an effective response.

After a year of being seizure-free, she began to develop generalized seizures and eyelid myoclonia — a form of epileptic seizure characterized by jerking of the eyelids, especially when directly exposed to daylight.

She was prescribed several other anti-epileptic therapies without success and was given piracetam (a neuroprotective and anti-convulsant agent, sold as Breinox) that, at a high dose of 60 g/day for two weeks, led to a dramatic improvement in both seizures and walking capacity (gait ataxia).

“She continued oral piracetam at 32 mg/day, topiramate at 75 mg/day, and VPA at 1,000 mg/day. Her recent brain MRI at the age of 37 years demonstrated prominent global cortical atrophy,” the researchers wrote.

Her brother also started Valproate treatment at 500 mg/day, and as the seizures continued, piracetam at 9.6 g/day and the anti-epileptic Topamax (TPM) at 100 mg/day were added to his regimen, leading to improvements in his seizures.

“Patients with adult-onset NCL may present with slowly progressive ataxia, persistent photosensitivity, and seizures without dementia or extrapyramidal findings. Brainstem abnormalities become more evident with time, in line with ataxia. Piracetam is effective for both seizures and ataxia,” the authors concluded.

  • Author Details
Patricia Inacio, PhD
Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.
×
Patricia Inacio, PhD
Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.
Print Friendly, PDF & EmailPrint This Page

Tagged adult-onset, ataxia, Clinical Evolution, long-term follow up, NCL, seizures, symptoms.

Post navigation

progranulinPrevious: Protein in Specific Cells Involved in Batten Disease Neurodegeneration, Mouse Study Suggests
rare disease and QoLNext:#ERDC2018 – When Treating Rare Disease Patients, Don’t Overlook Quality of Life, Panel Urges

Recent Posts

  • HHS Secretary Alex Azar Touts White House Efforts to Cure Rare Diseases

    December 6, 2019

  • Sanger sequencing, Batten

    Genetic Test Can Provide Definitive Diagnosis of Batten Disease, Canadian Study Suggests

    December 5, 2019

  • fruit fly model, Batten disease

    CLN7 Protein is Involved in Communication Between Nerve and Muscle Cells, Batten Disease Model Shows

    November 21, 2019

  • Rare Disease Film Festival Highlights Patient and Researcher Unity

    November 14, 2019

  • fat molecule for CLN3

    Fat Molecule May Help Fight CLN3 Disease, Mouse Study Suggests

    November 14, 2019

Featured

Canine Models of Batten Disease May Help to Develop New Therapeutic Approaches, Review Says

November 6, 2018

Batten canine models

Create your own user feedback survey

9 Things We Should Know About the Race to New Treatments

October 2, 2019

new treatments

Amicus CEO John Crowley Outlines Progress in Batten, Pompe, Fabry Therapies

August 23, 2019

Batten Disease News

BioNews Services, LLC

1601 Market St.
Suite 20B103
Philadelphia, PA 19103
Email: [email protected]
Phone: 1-800-936-1363

  • About Us
  • Our Team
  • Our Guiding Ethics
  • Write For Us – Become a Columnist
  • Contact Us
  • Terms of Service
  • Privacy Policy
  • Disable Notifications

Disclaimer:

Batten Disease News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Copyright © 2013-2019 All rights reserved.

Pin It on Pinterest

Share This
  • Facebook
  • Twitter
  • Pinterest
  • LinkedIn
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. We never use your cookies for creepy ad retargeting that follows you around the web. OkRead more